Literature DB >> 28069350

Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Fabiane Klem1, Akhilesh Wadhwa2, Larry J Prokop2, Wendy J Sundt2, Gianrico Farrugia2, Michael Camilleri2, Siddharth Singh3, Madhusudan Grover4.   

Abstract

BACKGROUND & AIMS: Foodborne illness affects 15% of the US population each year, and is a risk factor for irritable bowel syndrome (IBS). We evaluated risk of, risk factors for, and outcomes of IBS after infectious enteritis.
METHODS: We performed a systematic review of electronic databases from 1994 through August 31, 2015 to identify cohort studies of the prevalence of IBS 3 months or more after infectious enteritis. We used random-effects meta-analysis to calculate the summary point prevalence of IBS after infectious enteritis, as well as relative risk (compared with individuals without infectious enteritis) and host- and enteritis-related risk factors.
RESULTS: We identified 45 studies, comprising 21,421 individuals with enteritis, followed for 3 months to 10 years for development of IBS. The pooled prevalence of IBS at 12 months after infectious enteritis was 10.1% (95% confidence interval [CI], 7.2-14.1) and at more than 12 months after infectious enteritis was 14.5% (95% CI, 7.7-25.5). Risk of IBS was 4.2-fold higher in patients who had infectious enteritis in the past 12 months than in those who had not (95% CI, 3.1-5.7); risk of IBS was 2.3-fold higher in individuals who had infectious enteritis more than 12 months ago than in individuals who had not (95% CI, 1.8-3.0). Of patients with enteritis caused by protozoa or parasites, 41.9% developed IBS, and of patients with enteritis caused by bacterial infection, 13.8% developed IBS. Risk of IBS was significantly increased in women (odds ratio [OR], 2.2; 95% CI, 1.6-3.1) and individuals with antibiotic exposure (OR, 1.7; 95% CI, 1.2-2.4), anxiety (OR, 2; 95% CI, 1.3-2.9), depression (OR, 1.5; 95% CI, 1.2-1.9), somatization (OR, 4.1; 95% CI, 2.7-6.0), neuroticism (OR, 3.3; 95% CI, 1.6-6.5), and clinical indicators of enteritis severity. There was a considerable level of heterogeneity among studies.
CONCLUSIONS: In a systematic review and meta-analysis, we found >10% of patients with infectious enteritis develop IBS later; risk of IBS was 4-fold higher than in individuals who did not have infectious enteritis, although there was heterogeneity among studies analyzed. Women-particularly those with severe enteritis-are at increased risk for developing IBS, as are individuals with psychological distress and users of antibiotics during the enteritis.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Functional Gastrointestinal Disorders; Gastrointestinal Infections; Microbes; Post-Infectious Irritable Bowel Syndrome

Mesh:

Substances:

Year:  2017        PMID: 28069350      PMCID: PMC5367939          DOI: 10.1053/j.gastro.2016.12.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  65 in total

1.  The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection.

Authors:  Mark R Borgaonkar; David C Ford; John K Marshall; Elizabeth Churchill; Stephen M Collins
Journal:  Dig Dis Sci       Date:  2006-06-07       Impact factor: 3.199

2.  Postinfectious functional gastrointestinal disorders in children: a multicenter prospective study.

Authors:  Licia Pensabene; Valentina Talarico; Daniela Concolino; Domenico Ciliberto; Angelo Campanozzi; Teresa Gentile; Vincenzo Rutigliano; Silvia Salvatore; Annamaria Staiano; Carlo Di Lorenzo
Journal:  J Pediatr       Date:  2015-02-04       Impact factor: 4.406

3.  Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

4.  Irritable bowel syndrome in persons who acquired trichinellosis.

Authors:  Mujde Soyturk; Hale Akpinar; Oguz Gurler; Edoardo Pozio; Ismail Sari; Servet Akar; Mesut Akarsu; Merih Birlik; Fatos Onen; Nurullah Akkoc
Journal:  Am J Gastroenterol       Date:  2007-02-21       Impact factor: 10.864

5.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water.

Authors:  Amit X Garg; John Marshall; Marina Salvadori; Heather R Thiessen-Philbrook; Jennifer Macnab; Rita S Suri; R Brian Haynes; Janet Pope; William Clark
Journal:  J Clin Epidemiol       Date:  2006-01-27       Impact factor: 6.437

7.  The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study.

Authors:  In Su Jung; Hee Sun Kim; Hyojin Park; Sang In Lee
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

8.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

9.  Post-infectious functional gastrointestinal disorders in children.

Authors:  Miguel Saps; Licia Pensabene; Lucio Di Martino; Annamaria Staiano; Joshua Wechsler; Xiaotian Zheng; Carlo Di Lorenzo
Journal:  J Pediatr       Date:  2008-02-14       Impact factor: 4.406

10.  Depression and abdominal pain in IBS patients: the mediating role of catastrophizing.

Authors:  Jeffrey M Lackner; Brian M Quigley; Edward B Blanchard
Journal:  Psychosom Med       Date:  2004 May-Jun       Impact factor: 4.312

View more
  99 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 2.  Antidepressants in inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Alexander C Ford; Douglas A Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-18       Impact factor: 46.802

3.  Diet and exercise: Clinical studies and molecular biology show that diet and other lifestyle changes have significant potential for treating metabolic diseases.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2019-03-12       Impact factor: 8.807

Review 4.  Post-infection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition.

Authors:  Uday C Ghoshal; M Masudur Rahman
Journal:  Indian J Gastroenterol       Date:  2019-04

Review 5.  Enterotoxigenic Escherichia coli Infections.

Authors:  James M Fleckenstein; F Matthew Kuhlmann
Journal:  Curr Infect Dis Rep       Date:  2019-03-04       Impact factor: 3.725

6.  Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS.

Authors:  Shoko Edogawa; Adam L Edwinson; Stephanie A Peters; Lakshmikanth L Chikkamenahalli; Wendy Sundt; Sara Graves; Sakteesh V Gurunathan; Margaret Breen-Lyles; Stephen Johnson; Roy Dyer; Rondell Graham; Jun Chen; Purna Kashyap; Gianrico Farrugia; Madhusudan Grover
Journal:  Gut       Date:  2019-03-28       Impact factor: 23.059

7.  Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.

Authors:  Walter Morales; Ali Rezaie; Gillian Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2019-05-31       Impact factor: 3.199

8.  Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum?

Authors:  Gabrio Bassotti; Lara Macchioni; Lanfranco Corazzi; Pierfrancesco Marconi; Katia Fettucciari
Journal:  Cell Mol Life Sci       Date:  2017-12-28       Impact factor: 9.261

Review 9.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

10.  Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice.

Authors:  Lijun Du; Yanqin Long; John J Kim; Binrui Chen; Yubin Zhu; Ning Dai
Journal:  Dig Dis Sci       Date:  2018-11-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.